IN2014CN00572A - - Google Patents

Info

Publication number
IN2014CN00572A
IN2014CN00572A IN572CHN2014A IN2014CN00572A IN 2014CN00572 A IN2014CN00572 A IN 2014CN00572A IN 572CHN2014 A IN572CHN2014 A IN 572CHN2014A IN 2014CN00572 A IN2014CN00572 A IN 2014CN00572A
Authority
IN
India
Prior art keywords
compounds
infections
salts
treating
formula
Prior art date
Application number
Other languages
English (en)
Inventor
Pek Yoke Chong
John F Miller
Andrew James Peat
John Brad Shotwell
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47746761&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2014CN00572(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of IN2014CN00572A publication Critical patent/IN2014CN00572A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • C07F5/025Boronic and borinic acid compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/69Boron compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D307/85Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • C07F5/027Organoboranes and organoborohydrides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • C07F5/04Esters of boric acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
IN572CHN2014 2011-08-19 2012-08-10 IN2014CN00572A (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161525440P 2011-08-19 2011-08-19
US201261650681P 2012-05-23 2012-05-23
PCT/US2012/050268 WO2013028371A1 (en) 2011-08-19 2012-08-10 Benzofuran compounds for the treatment of hepatitis c virus infections

Publications (1)

Publication Number Publication Date
IN2014CN00572A true IN2014CN00572A (hr) 2015-04-03

Family

ID=47746761

Family Applications (1)

Application Number Title Priority Date Filing Date
IN572CHN2014 IN2014CN00572A (hr) 2011-08-19 2012-08-10

Country Status (37)

Country Link
US (2) US8927593B2 (hr)
EP (2) EP3199531A1 (hr)
JP (2) JP6367712B2 (hr)
KR (1) KR101913800B1 (hr)
CN (1) CN103732065B (hr)
AR (1) AR087563A1 (hr)
AU (1) AU2012299295B2 (hr)
BR (1) BR112014002845A2 (hr)
CA (1) CA2844086A1 (hr)
CL (2) CL2014000393A1 (hr)
CO (1) CO6862153A2 (hr)
CR (1) CR20140078A (hr)
CY (1) CY1118399T1 (hr)
DK (1) DK2744332T3 (hr)
DO (1) DOP2014000034A (hr)
EA (1) EA032841B1 (hr)
ES (1) ES2611731T3 (hr)
HR (1) HRP20161743T1 (hr)
HU (1) HUE030300T2 (hr)
IL (1) IL230487B (hr)
IN (1) IN2014CN00572A (hr)
JO (1) JO3281B1 (hr)
LT (1) LT2744332T (hr)
MA (1) MA35443B1 (hr)
ME (1) ME02588B (hr)
MX (1) MX354676B (hr)
PE (1) PE20141201A1 (hr)
PL (1) PL2744332T3 (hr)
PT (1) PT2744332T (hr)
RS (1) RS55462B1 (hr)
SG (1) SG10201606883QA (hr)
SI (1) SI2744332T1 (hr)
SM (1) SMT201700028B (hr)
TW (1) TWI538915B (hr)
UY (1) UY34274A (hr)
WO (1) WO2013028371A1 (hr)
ZA (1) ZA201401020B (hr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2843502C (en) * 2011-08-17 2019-01-15 Glaxosmithkline Llc Therapeutic methods for treating hepatitis c virus infection
WO2013028371A1 (en) 2011-08-19 2013-02-28 Glaxo Group Limited Benzofuran compounds for the treatment of hepatitis c virus infections
BR112017009504A2 (pt) 2014-11-10 2018-02-06 Glaxosmithkline Ip No 2 Ltd métodos para tratar e para curar uma infecção por hcv, e, composição farmacêutica.
US20170312297A1 (en) * 2014-11-10 2017-11-02 Glaxosmithkline Intellectual Property (No. 2) Limited Long Acting Pharmaceutical Compositions For Hepatitis C
KR20180006522A (ko) 2016-07-07 2018-01-18 삼성디스플레이 주식회사 액정 조성물 및 이를 포함하는 액정 표시 장치
WO2018026656A1 (en) * 2016-08-01 2018-02-08 University Of Pittsburgh -Of The Commonwealth System Of Higher Education Boryl ethers, carbonates, and cyclic acetals as oxidatively-triggered drug delivery vehicles
ES2898217T3 (es) * 2017-03-02 2022-03-04 Assembly Biosciences Inc Compuestos de sulfamida cíclica y métodos de uso de los mismos
IL276013B2 (en) * 2018-01-17 2024-03-01 Glaxosmithkline Ip Dev Ltd PI4KIIIBETA inhibitors
EP4049680A4 (en) * 2019-10-25 2024-01-10 Sumitomo Pharma Co Ltd NEW SUBSTITUTED CONDENSED RING CONNECTION
CN111026203B (zh) * 2019-12-02 2021-01-26 宁波德晶元科技有限公司 一种适用于真空热水壶的加热控制方法与系统

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
EP1196436A2 (en) * 1999-07-07 2002-04-17 Bristol-Myers Squibb Pharma Company Peptide boronic acid inhibitors of hepatitis c virus protease
DK3078667T3 (en) 2001-01-25 2019-01-07 The United States Of America Represented By The Sec Dep Of Health And Human Services Formulation of boric acid compounds
NZ539727A (en) 2002-11-01 2008-01-31 Viropharma Inc Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis C viral infections and associated diseases
WO2008051244A2 (en) 2005-12-01 2008-05-02 Wyeth Anthranilic acid derivatives useful in treating infection with hepatitis c virus
PL1988779T3 (pl) 2006-02-16 2015-10-30 Anacor Pharmaceuticals Inc Małe cząsteczki zawierające bor jako środki przeciwzapalne
WO2007131072A2 (en) * 2006-05-02 2007-11-15 Anacor Pharmaceuticals, Inc. Hydrolytically-resistant boron-containing therapeutics and methods of use
US20070286822A1 (en) 2006-06-12 2007-12-13 Anacor Pharmaceuticals Inc. Compounds for the Treatment of Periodontal Disease
CN103450077B (zh) 2007-06-08 2016-07-06 满康德股份有限公司 IRE-1α抑制剂
GB0719366D0 (en) * 2007-10-03 2007-11-14 Smithkline Beecham Corp Compounds
WO2009111676A2 (en) 2008-03-06 2009-09-11 Anacor Pharmaceuticals, Inc Boron-containing small molecules as anti-inflammatory agents
EP2245023B1 (en) * 2008-02-14 2011-12-28 F. Hoffmann-La Roche AG Heterocyclic antiviral compounds
WO2009137493A1 (en) 2008-05-05 2009-11-12 Wyeth 2-substituted benzofuran compounds to treat infection with hepatitis c virus
WO2009137500A1 (en) * 2008-05-05 2009-11-12 Wyeth 6-substituted benzofuran compounds to treat infection with hepatitis c virus
US7737157B2 (en) 2008-08-29 2010-06-15 Hutchison Medipharma Enterprises Limited Pyrimidine compounds
WO2010027975A1 (en) 2008-09-04 2010-03-11 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
WO2011050284A1 (en) * 2009-10-23 2011-04-28 Glaxosmithkline Llc Pyrazolylpyridine antiviral agents
WO2011103063A1 (en) * 2010-02-19 2011-08-25 Glaxo Group Limited Therapeutic compounds
WO2011106986A1 (en) 2010-03-02 2011-09-09 Merck Sharp & Dohme Corp. Inhibitors of hepatitis c virus ns5b polymerase
WO2011106929A1 (en) 2010-03-02 2011-09-09 Merck Sharp & Dohme Corp. Inhibitors of hepatitis c virus ns5b polymerase
TW201136919A (en) 2010-03-02 2011-11-01 Merck Sharp & Amp Dohme Corp Inhibitors of hepatitis C virus NS5B polymerase
AU2011329485A1 (en) * 2010-11-18 2013-04-18 Glaxo Group Limited Compounds
WO2012067664A1 (en) 2010-11-18 2012-05-24 Glaxo Group Limited Compounds
CA2843502C (en) * 2011-08-17 2019-01-15 Glaxosmithkline Llc Therapeutic methods for treating hepatitis c virus infection
WO2013025975A1 (en) * 2011-08-17 2013-02-21 Glaxosmithkline Llc Combination treatments for hepatitis c
WO2013028371A1 (en) 2011-08-19 2013-02-28 Glaxo Group Limited Benzofuran compounds for the treatment of hepatitis c virus infections

Also Published As

Publication number Publication date
JO3281B1 (ar) 2018-09-16
LT2744332T (lt) 2017-01-10
SI2744332T1 (sl) 2017-01-31
BR112014002845A2 (pt) 2017-02-21
RS55462B1 (sr) 2017-04-28
ZA201401020B (en) 2020-11-25
EP2744332B1 (en) 2016-10-26
JP6367712B2 (ja) 2018-08-01
AU2012299295B2 (en) 2016-03-31
TW201321390A (zh) 2013-06-01
DK2744332T3 (en) 2017-01-16
ES2611731T3 (es) 2017-05-10
PT2744332T (pt) 2017-01-24
IL230487B (en) 2019-06-30
EA032841B1 (ru) 2019-07-31
SG10201606883QA (en) 2016-10-28
CL2017000293A1 (es) 2017-10-06
CY1118399T1 (el) 2017-06-28
CR20140078A (es) 2014-03-20
PE20141201A1 (es) 2014-10-03
WO2013028371A1 (en) 2013-02-28
CN103732065B (zh) 2016-10-26
PL2744332T3 (pl) 2017-03-31
CA2844086A1 (en) 2013-02-28
JP2014527529A (ja) 2014-10-16
AR087563A1 (es) 2014-04-03
KR101913800B1 (ko) 2018-11-01
EP2744332A1 (en) 2014-06-25
US8927593B2 (en) 2015-01-06
EP2744332A4 (en) 2015-01-14
EA201490213A1 (ru) 2014-07-30
US20150080343A1 (en) 2015-03-19
ME02588B (me) 2017-06-20
MX354676B (es) 2018-03-15
AU2012299295A1 (en) 2014-02-20
KR20140054287A (ko) 2014-05-08
IL230487A0 (en) 2014-03-31
MA35443B1 (fr) 2014-09-01
HRP20161743T1 (hr) 2017-02-24
DOP2014000034A (es) 2014-06-01
UY34274A (es) 2013-04-05
TWI538915B (zh) 2016-06-21
CN103732065A (zh) 2014-04-16
SMT201700028B (it) 2017-03-08
US9682999B2 (en) 2017-06-20
US20130237501A1 (en) 2013-09-12
EP3199531A1 (en) 2017-08-02
JP2017125010A (ja) 2017-07-20
CL2014000393A1 (es) 2014-08-01
HUE030300T2 (en) 2017-04-28
CO6862153A2 (es) 2014-02-10
MX2014001989A (es) 2014-02-27

Similar Documents

Publication Publication Date Title
IN2014CN00572A (hr)
MY170941A (en) Pyrimidine derivatives for the treatment of viral infections
IN2014MN02652A (hr)
IN2014MN02658A (hr)
IN2015DN01156A (hr)
IN2014MN02657A (hr)
PH12015500274A1 (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
IN2014MN00862A (hr)
PH12015500713B1 (en) Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases
PH12015500724A1 (en) 1, 2, 4-triazine derivatives for the treatment of viral infections
MX2015011193A (es) Compuestos antivirales.
WO2011160024A3 (en) Compounds useful as antiviral agents, compositions, and methods of use
WO2011150190A3 (en) Hcv inhibitor compounds and methods of use thereof
WO2013106689A8 (en) Hcv ns3 protease inhibitors
PH12014502551B1 (en) Oligonucleotide chelate complex-polypeptide compositions and methods
MX2015011198A (es) Compuestos antivirales.
BR112014015582A8 (pt) compostos antivirais
IN2015DN02109A (hr)
MX2015010892A (es) Compuestos antivirales.
MX2015010790A (es) Derivados de anilina sustituidos con n-heteroarilo como antivirales de vhc.
MX2015011125A (es) Compuestos antivirales.
MX2015011126A (es) Compuestos antivirales.
CU20140133A7 (es) Composiciones y métodos de polipéptidos-complejo de quelato de oligonucleótido